Inventiva SA
(NASDAQ:IVA)
$6.175
0.085[1.40%]
At close: Feb 3
$6.25
0.0750[1.21%]
After Hours: 5:49PM EDT
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.100 - 6.25052 Wk Range0 - 13.660Open / Close6.250 / 6.100Float / Outstanding36.560M / 42.134M
Vol / Avg.2.289K / 7.858KMkt Cap260.178MP/E-50d Avg. Price4.940
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.560MEPS-1.390
Globe Newswire - Jun 7, 2022, 4:00PM
Seeking Alpha - Oct 17, 2022, 1:23PM
Seeking Alpha - Oct 7, 2022, 8:54AM
Seeking Alpha - Sep 22, 2022, 4:36PM
TipRanks - Jun 29, 2022, 12:35PM
Sector: Health Care.Industry: Biotechnology
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-06
REV
H1 2022Est.ActualSurprise
EPS-0.790
REV73.308K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inventiva (IVA) stock?

A

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inventiva's (IVA) competitors?

Q

What is the target price for Inventiva (IVA) stock?

A

The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Friday, September 23, 2022. The analyst firm set a price target for 36.00 expecting IVA to rise to within 12 months (a possible 483.00% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inventiva (IVA)?

A

The stock price for Inventiva (NASDAQ: IVA) is $6.175 last updated February 3, 2023 at 8:00 PM UTC.

Q

Does Inventiva (IVA) pay a dividend?

A

There are no upcoming dividends for Inventiva.

Q

When is Inventiva (NASDAQ:IVA) reporting earnings?

A

Inventiva’s FY earnings are confirmed for Monday, March 6, 2023.

Q

Is Inventiva (IVA) going to split?

A

There is no upcoming split for Inventiva.

Q

What sector and industry does Inventiva (IVA) operate in?

A

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.